Sera Prognostics, Inc. (SERA) is a leading-edge health diagnostics company focused on women's health and specifically, pregnancy. The company is renowned for their commitment to improve the health of pregnant women and their babies through advanced predictive analytics. SERA's mission is to revolutionize care management by providing actionable intelligence to doctors about prospective health concerns, helping mitigate potential risks and complications during pregnancy.
SERA Prognostics was founded in 2008 and is headquartered in Salt Lake City, Utah. The company stands out in the healthcare industry due to its proprietary technology that allows it to identify and analyze specific protein biomarkers in a patient's bloodstream. These biomarkers aid in predicting potential onset conditions such as preterm birth (PTB) and preeclampsia, both serious complications linked to premature delivery.
SERA's main product, the PreTRM® Test, is revolutionary. The PreTRM® test is the first and only clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. This test provides doctors with critical information that conventional methods fail to supply, enabling early interventions and health management.
Additionally, SERA Prognostics is pioneering the development of other innovative diagnostic tests. The company is in the process of developing tests for the prediction of other pregnancy complications such as gestational diabetes.
Believing in collaboration, SERA has initiated global partnerships with several reputed pharmaceutical and diagnostics companies. These alliances facilitate the advancement of SERA’s diagnostics portfolio and enable it to extend its reach in different localities worldwide.
SERA Prognostics is a proud member of the diagnostics community, actively participating in industry-related events and forums. This participation demonstrates SERA’s commitment to staying at the forefront of industry advancements and innovations, as well as to fostering dialogue around the critical importance of women's health.
In summary, SERA Prognostics, Inc. is a pioneering healthcare company with a profound focus on pregnancy-related health complications. Its ground-breaking technologies, led by the PreTRM® Test, are helping to shape the future of maternal and newborn health. By developing early prediction tests, SERA is working relentlessly to reduce the risks and costs associated with preterm birth and other pregnancy-related complications, striving for healthier futures for both mothers and babies.